2021 Southern Hemisphere Influenza Vaccine

The Defense Logistics Agency- Troop Support is seeking sources capable of providing Southern Hemisphere Influenza Vaccine. Shall be a quadrivalent vaccine, licensed by the FDA, intended for active immunization for the prevention of influenza for the Southern Hemisphere. Shall meet the minimum formula for the influenza vaccine as determined by the FDA’s Vaccines and Related Biological Products Advisory Committee. Shall be a pre-measured 0.5 ML dose, each dose shall be pre-filled in a commercially available syringe for intramuscular administration in healthy individuals aged 6 months and older.  Shall be free of thimerosal or other preservatives.  Shall be shipped refrigerated between 2° and 8° C.  The vaccine must not be frozen.   Shall be one package containing 10 pre-filled syringes as the unit of issue.  Product shall be both FDA Approved and ACIP Recommended.

DLA Troop Support has an annual estimated requirement for Southern Hemisphere Influenza Vaccine of 25,000 doses for the 2021 season.  The vaccine shall be delivered to the Defense Distribution Center (DDC) in Susquehanna, PA.

This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not be returned.

*** Currently Marketed Southern Hemisphere Influenza Vaccine ***

If your firm currently markets Southern Hemisphere Influenza Vaccine, please provide information with respects to the following:

1. Place of Manufacture
2. Estimated Annual Capacity
3. FDA registration information
4. Product Name and description including description of any special features
5. Current unit sale price
6. Estimated inventory level and storage requirements
7. Delivery days for this item
8. Capacity for surge and sustainment requirement

 *** New Products Under Development ***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture product described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protect Critical infrastructure information (PCII) Program outlined in the Critical Infrastructure Information Act 2002.  

Your response to this RFI may be submitted electronically in pdf format and emailed to the Contracting Officer jenna.wesolowski@dla.mil.